Furiex Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. Food and Drug Administration for Avarofloxacin (JNJ-Q2)

[at noodls] – MORRISVILLE, N.C. (February 25, 2013) – Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) announced today that avarofloxacin (USAN adopted, INN approval pending), has been granted Qualified Infectious Disease … more

View todays social media effects on FURX

View the latest stocks trending across Twitter. Click to view dashboard

See who Furiex is hiring next, click here to view